Napatrin (ketamine/sufentanil) / Cessatech - LARVOL DELTA

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - P2/3 | N=155 | Completed | Sponsor: Cessatech A/S | Recruiting ➔ Completed

Trial completion • Pain • Pediatrics

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - P2/3 | N=150 | Recruiting | Sponsor: Cessatech A/S | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Pain • Pediatrics

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - P2/3 | N=150 | Recruiting | Sponsor: Cessatech A/S | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Sep 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Pain • Pediatrics

Developing a novel pediatric intranasal analgesic using PK-PD modeling to obtain adequate dosing (IASP 2024) - "The integration of PK/PD modelling provides a robust novel framework for understanding drug behavior across demographics. The modelling supports that CT001 has the potential to become a rapid-acting and needle-free effective contribution in the management of acute pain in pediatric patients in the ER and for procedural pain. The combination of a favorable safety profile and the intranasal spray device, with which it is being co-developed, ensuring adequate dosing with minimal risk of handling errors, also add to the future potential clinical benefit of this treatment option."

Clinical • PK/PD data • CNS Disorders • Depression • Pain • Pediatrics • Psychiatry

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - P2/3 | N=150 | Recruiting | Sponsor: Cessatech A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Pain • Pediatrics

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - P2/3 | N=150 | Not yet recruiting | Sponsor: Cessatech A/S

New P2/3 trial • Pain • Pediatrics

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - P2/3 | N=220 | Completed | Sponsor: Cessatech A/S | Recruiting ➔ Completed

Trial completion • Pain

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - P2/3 | N=220 | Recruiting | Sponsor: Cessatech A/S | Trial completion date: Apr 2023 ➔ Aug 2023 | Trial primary completion date: Apr 2023 ➔ Aug 2023

Trial completion date • Trial primary completion date • Pain

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - P2/3 | N=220 | Recruiting | Sponsor: Cessatech A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Pain

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - P2/3 | N=220 | Not yet recruiting | Sponsor: Cessatech A/S

New P2/3 trial • Pain

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures (clinicaltrials.gov) - P2 | N=25 | Completed | Sponsor: Cessatech A/S | Recruiting ➔ Completed

Trial completion